• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tpoxx (tecovirimat)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tpoxx (tecovirimat)

  • Profile

Profile

Contact Information

Contact: Siga Technologies
Website: https://www.siga.com/about-siga/#products

Currently Enrolling Trials

    Show More

    General Information

    Tpoxx (tecovirimat) is an antiviral drug against variola (smallpox) virus. 

    Tpoxx is specifically indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg. 

    Tpoxx is supplied as a capsule for oral administration. The recommended dose is as follows:

    Dosage for Adults and Pediatric Patients Weighing at Least 40 kg: 600 mg (three 200 mg capsules) taken twice daily orally for 14 days. Tpoxx should be taken within 30 minutes after a full meal of moderate or high fat.

    Dosage for Pediatric Patients: The recommended dosage for pediatric patients is based on weight starting at 13 kg, as seen below. The dose should be given twice daily orally for 14 days and should be taken within 30 minutes after a full meal of moderate or high fat. 

    Body Weight Dosage Number of Capsules Drug-Food Preparation
    13 kg to less
    than 25 kg
    200 mg twice
    daily
    Contents of 1 Capsule
    twice daily
    Mix 1 capsule of TPOXX with
    30 mL of liquid or soft food.
    Administer the whole mixture.
    25 kg to less
    than 40 kg
    400 mg twice
    daily
    Contents of 2 Capsules
    twice daily
    Mix 2 capsules of TPOXX with
    30 mL of liquid or soft food.
    Administer the whole mixture.
    40 kg and
    above
    600 mg twice
    daily
    Contents of 3 Capsules
    twice daily
    Mix 3 capsules of TPOXX with
    30 mL of liquid or soft food.
    Administer the whole mixture.

     

    Preparation for administration to pediatrics and those who cannot swallow capsules: capsules can be administered by carefully opening the capsule and mixing the entire contents in 30 mL of liquid (e.g., milk, chocolate milk) or soft food (e.g., apple sauce, yogurt). The entire mixture should be administered within 30 minutes of its preparation. 

    Mechanism of Action

    Tpoxx (tecovirimat) targets and inhibits the activity of the orthopoxvirus VP37 protein (encoded by and highly conserved in all members of the orthopoxvirus genus) and blocks its interaction with cellular Rab9 GTPase and TIP47, which prevents the formation of egress-competent enveloped virions necessary for cell-to-cell and long-range dissemination of virus.

    Side Effects

    Adverse effects associated with the use of Tpoxx may include, but are not limited to, the following:

    • headache
    • nausea
    • abdominal pain
    • vomiting

    Clinical Trial Results

    The effectiveness of Tpoxx for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. Therefore, the effectiveness of Tpoxx for treatment of smallpox disease was established based on results of adequate and well-controlled animal efficacy studies of non-human primates and rabbits infected with non-variola orthopoxviruses. Survival rates observed in the animal studies may not be predictive of survival rates in clinical practice.

    Efficacy studies were conducted in cynomolgus macaques infected with monkeypox virus, and New Zealand white (NZW) rabbits infected with rabbitpox virus. The primary efficacy endpoint for these studies was survival. In non-human primate studies, cynomolgus macaques were lethally challenged intravenously with 5 x 107 plaque-forming units of monkeypox virus; tecovirimat was administered orally once daily at a dose level of 10 mg/kg for 14 days, starting at Day 4, 5 or 6 post-challenge. In rabbit studies, NZW rabbits were lethally challenged intradermally with 1,000 plaque-forming units of rabbitpox virus; tecovirimat was administered orally once daily for 14 days at a dose level of 40 mg/kg, starting at Day 4 post-challenge. The timing of tecovirimat dosing in these studies was intended to assess efficacy when treatment is initiated after animals have developed clinical signs of disease, specifically dermal pox lesions in cynomolgus macaques, and fever in rabbits. Clinical signs of disease were evident in some animals at Day 2-3 post-challenge but were evident in all animals by Day 4 post-challenge. Survival was monitored for 3-6 times the mean time to death for untreated animals in each model. Treatment with tecovirimat for 14 days resulted in statistically significant improvement in survival relative to placebo, except when given to cynomolgus macaques starting at Day 6 post-challenge.

    Approval Date: 2018-07-01
    Company Name: Siga Technologies
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing